🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 53 Guangzhou 40 Beijing 33 Chengdu 13 Wuhan 10
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81 Clear sponsor filter
Site location
Shanghai53 Guangzhou40 Beijing33 Chengdu13 Wuhan10
All 42 locations
Target enrolment
to

Trials with a site in Guangzhou

40 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
NCT07783321Nasopharyngeal Carcinoma (NPC)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
404
Guangzhou
2026-09
Not yet open
A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal Carcinoma
NCT07797881Nasopharyngeal Carcinoma (NPC)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
60
Guangzhou
2026-09
Not yet open
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07827261Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
36
Guangzhou
2026-09
Not yet open
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
NCT07818499Diffuse Large B-Cell Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
204
Guangzhou, Suzhou
2026-09
Not yet open
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
NCT07818486Nasopharyngeal Carcinoma (NPC), Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
30
Chongqing, Guangzhou
2026-09
Not yet open
A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
NCT07739199Squamous Non-small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
200
Guangzhou, Wuhan
2026-08
Not yet open
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
NCT07739186Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
120
Guangzhou
2026-08
Not yet open
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
NCT07763652Gastrointestinal Tumors, Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Guangzhou
2026-08
Recruiting
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT07606612Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
31
Guangzhou
2026-06-11
Recruiting
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
NCT07518173HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
596
Guangzhou, Chengdu
2026-04-21
Recruiting
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
NCT07232420Non Small Cell Lung Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Guangzhou
2025-11-11
Recruiting
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
NCT07178795Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
440
Guangzhou
2025-09-29
Recruiting
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
NCT06891833HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
985
Bengbu, Hefei, Chongqing, Fuzhou, Guangzhou, Shenzhen, Liuzhou, Nanning
2025-06-05
Recruiting
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
NCT06957886HER2-low Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
566
Guangzhou, Changsha
2025-05-15
Recruiting
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
NCT06954077Gastrointestinal Tumor, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
45
Guangzhou
2025-05-15
Active, closed
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma
NCT06787664Chordoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
27
Guangzhou
2025-01-16
Active, closed
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
NCT06500026Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
722
Guangzhou
2024-08-07
Recruiting
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
NCT06500052Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Guangzhou
2024-07-24
Recruiting
A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06475131Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
21
Guangzhou
2024-07-18
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
NCT06475300Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
570
Guangzhou
2024-06-25
Active, closed
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
NCT06445400HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
83
Guangzhou
2024-06-19
Active, closed
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
NCT06382116Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
432
Guangzhou
2024-05-22
Active, closed
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
NCT06316531HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
274
Guangzhou
2024-05-08
Active, closed
A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06114511Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
78
Guangzhou
2024-04-24
Recruiting
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
NCT05956587Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
121
Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha
2024-01-29
Active, closed
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
NCT06118333Nasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
386
Guangzhou
2023-12-04
Active, closed
A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
NCT05943795Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
589
Guangzhou, Hangzhou
2023-07-14
Active, closed
A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
NCT05627856NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
4
Guangzhou
2023-02-21
Active, closed
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
NCT05485753Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
7
Beijing, Guangzhou, Zhengzhou
2023-02-10
Recruiting
A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT05470348Breast Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Guangzhou, Shanghai
2022-08-11
Active, closed
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors
NCT05385692Locally Advanced or Metastatic Digestive Tract Tumors, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
22
Guangzhou
2022-06-01
Active, closed
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
NCT05339685Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
82
Bengbu, Guangzhou, Guilin, Wuhan, Yueyang, Changchun, Hangzhou
2022-05-20
Active, closed
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
NCT05104775Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Guangzhou, Guiyang, Shijiazhuang, Wuhan, Shenyang, Shanghai, Yibin
2022-02-09
Active, closed
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
NCT05020769Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
14
Guangzhou, Guilin, Guangdong
2022-01-06
Active, closed
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
NCT05020457Non Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
69
Chongqing, Guangzhou, Guilin, Jinan, Taizhou
2021-12-07
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
NCT05194982Locally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
570
Chongqing, Guangzhou, Wuhan, Changsha, Shanghai, Taiyuan
2021-11-29
Active, closed
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer
NCT05160545Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
36
Bengbu, Dongguan, Guangzhou, Changsha, Chengdu
2021-11-26
Recruiting
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
NCT04794972Recurrent Glioma, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Guangzhou, Shenzhen, Xian, Chengdu
2021-04-14
Active, closed
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT04606433Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Active, closed
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
NCT04603287Locally Advanced or Metastatic Epithelial Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Guangzhou, Chengdu, Hangzhou
2020-04-17
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

14 of the 40 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 8 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 40 studies
PhaseStudiesRecruitingShare
Phase 115837.5%
Phase 39322.5%
Phase 27217.5%
Phase 1/25012.5%
Phase 2/34110%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.4014
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.